Investing in the pharmaceutical world means trying to invest as a product gets closer to completing FDA trials and approvals. In many respects, this is a wise strategy as a negative review by the FDA can kill a drug and its sponsor right along with it.

Anavex Life Sciences Corp (OTCBB: AVXL) will move to human clinical trials for its Alzheimer’s drug in early 2009 after preclinical studies on mice prove promising.

Popular conceptions of value-investing are debatable. How can you be sanguine that future projections about any stock are reliable? Here is a small-capital example from Bethesda, MD that you can use. It demonstrates the powers of adaptability and innovation in building the best platforms for business.

Bio-Imaging Technologies, Inc. (BITI) is a contract healthcare service organization that provides support to the pharmaceutical, biotechnology and medical device industries during clinical trial processes. Bio-Imaging reported second quarter results this morning that surpassed analysts’ estimates.

The author discusses the hot biotech stocks you don't want to miss based on the companies Gene Marcial introduced in his book "7 Commandments of Stock Investing". He talks about the company background and its rational behind its attraction.